



## Original Contribution

# Neonatal Genome-Wide Methylation Patterns in Relation to Birth Weight in the Norwegian Mother and Child Cohort

**Stephanie M. Engel\***, **Bonnie R. Joubert**, **Michael C. Wu**, **Andrew F. Olshan**, **Siri E. Håberg**, **Per Magne Ueland**, **Wenche Nystad**, **Roy M. Nilsen**, **Stein Emil Vollset**, **Shyamal D. Peddada**, and **Stephanie J. London\***

\* Correspondence to Dr. Stephanie M. Engel, Campus Box 7435, Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7435 (e-mail: stephanie.engel@unc.edu); or Dr. Stephanie London, National Institute of Environmental Health Sciences, PO Box 12233, MD A3-05, Research Triangle Park, NC 27709 (e-mail: london2@niehs.nih.gov).

Initially submitted July 25, 2013; accepted for publication December 18, 2013.

Although epigenetic regulation plays a critical role in embryonic development, few studies have examined the relationship of epigenome-wide methylation with fetal growth. Using the Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, California) in a substudy of 1,046 infants from the Norwegian Mother and Child Cohort Study (MoBa) enrolled between 1999 and 2008, we examined epigenome-wide cord blood DNA methylation in relation to birth weight. In multivariable-adjusted robust linear regression models, we identified differential methylation at 19 cytosine-guanine dinucleotides (CpGs) associated with either decreased (AT-rich interactive domain 5B (*MRF1*-like) (*ARID5B*), 2 CpGs) or increased (x-ray repair complementing defective repair in Chinese hamster cells 3 (*XRCC3*), 4 CpGs) birth weight. *ARID5B* knockout mice have less adipose tissue and significantly lower weight in the postnatal period. *XRCC3* plays a key role in the maintenance of chromosome stability and the repair of DNA damage. Although there are fewer data on the other implicated genes, many of these genes have been shown to have roles in developmental processes. This constitutes the largest and most robust study of birth weight using an epigenome-wide methylation platform and offers potential insights into epigenetic mechanisms of fetal growth.

birth weight; cord blood; epigenetics; methylation; MoBa; Norwegian Mother and Child Cohort Study

Abbreviations: CpG, cytosine-guanine dinucleotide; MoBa, Norwegian Mother and Child Cohort Study.

Epigenetic pathways regulate fetal development by controlling the expression of genes (1), facilitating both precisely timed and highly coordinated developmental processes (2). The most well-characterized of these epigenetic pathways is DNA methylation, the addition of a methyl group usually to cytosines in cytosine-guanine dinucleotide (CpG) sites (3). The relationship between CpG methylation and gene expression is complex and incompletely understood. Recent studies indicate that methylation at promoter and island regions tends to result in gene silencing; however, methylation in gene bodies tends to enhance gene expression (4–6). Loss of methylation at specific imprinted regions leads to serious growth-related congenital anomalies, such as Beckwith-Wiedemann and Silver-Russell syndromes (7, 8). However, there are

limited data in humans on the role of more modest variability in DNA methylation status in the growth and development of the fetus.

Although some portion of epigenetic lability is under genetic control (9), epigenomic consequences of exposures experienced in utero (10–12) have been documented in humans. For example, maternal depression (13) and smoking during pregnancy (11), both of which are predictors of reduced birth weight, have been associated with altered methylation profiles in either gene-specific (13) or epigenome-scale (11) investigations. In particular, Joubert et al. (11) identified significant associations between maternal smoking in pregnancy and differential methylation in genes involved in fundamental developmental processes. Together, these

results support the hypothesis that birth weight, and/or pathways leading to birth weight, may be affected by differences in methylation.

A few studies have begun to examine the associations of gene-specific methylation with birth weight. Targeted investigations have involved genes hypothesized to play key roles in growth (e.g., insulinlike growth factor 2), and/or that may be sensitive to famine exposure in pregnancy (*GNAS* antisense RNA 1 (*GNASAS*), *INS-IGF2* readthrough (*INS-IGF2*), and leptin (*LEP*)). However, studies have thus far not provided consistent evidence of an association with birth weight in humans (14–16). Recently, 2 epigenome-scale investigations of methylation in relation to birth weight have been published, although both had relatively small study populations and lacked adjustment for potentially important confounders. None of the principal findings in these studies overlap (17, 18).

We undertook an investigation of the relationship between CpG-specific cord blood DNA methylation and birth weight using the Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, California) among 1,046 newborns from the Norwegian Mother and Child Cohort Study (MoBa).

## METHODS

### Study population

MoBa enrolled more than 100,000 women between 1999 and 2008. Study design and selection characteristics have been described in detail elsewhere (19, 20). Women were invited by mail to participate prior to their routine ultrasonography examinations at their local hospitals, usually scheduled at approximately 18 weeks' gestation. Participation rates varied by study year (20) but averaged 38.5%. Exposure-related information was collected by questionnaire at the first enrollment visit and then again at approximately 30 weeks' gestation. Information on dietary folate intake was collected using a semiquantitative food frequency questionnaire returned by the mothers at approximately 18–22 gestational weeks. The food frequency questionnaire consisted of 263 questions about 255 food items and was designed to capture dietary habits and intakes of dietary supplements during the first 4–5 months of pregnancy (21, 22). Methods regarding calculation of nutrient and energy intakes have been previously described (21, 22). Briefly, nutrient and energy intakes were calculated using FoodCalc (<http://www.ibt.ku.dk/jesper/FoodCalc/Default.htm>) and the Norwegian Food Composition Table (23). We adjusted for folate intake from foods. Measurement of plasma folate status was obtained from maternal blood samples collected at the enrollment visit (at approximately 18 weeks' gestation). Plasma folate was measured using a microbiological assay with a chloramphenicol-resistant strain of *Lactobacillus casei* (24). The assay determines biologically active folate species, predominantly 5-methyltetrahydrofolate, and has a coefficient of variation of 4% within day and 5% between days at population median concentration (24). The Medical Birth Registry of Norway receives mandatory information on all deliveries at hospitals using a standardized birth notification form (25). This form includes demographic information about the mother and father, information about the mother's health before and during

pregnancy, including chronic diseases and pregnancy complications, and information on delivery characteristics.

Within MoBa, a nested case-cohort subset was established to examine prenatal risk factors for asthma at 3 years of age (26), which included 507 singleton asthma cases and a reference population of 1,455 singletons randomly selected from the MoBa population with 3-year follow-up data available. The current study is based on the subset of these singletons for whom cord blood and valid methylation data and data on covariates relevant to analysis of birth weight were available ( $n = 1,046$ ) (11). This study was approved by the University of North Carolina Chapel Hill Office of Human Research Ethics (Chapel Hill, North Carolina).

### DNA methylation

DNA methylation at 485,577 cytosine positions (CpG sites) was measured in cord blood from the MoBa samples using the Infinium HumanMethylation450 BeadChip (27, 28). Bisulfite conversion was performed using the EZ-96 DNA methylation kit (Zymo Research Corporation, Irvine, California) according to manufacturer instructions and was checked per methods previously described (27). For each sample, the methylation level at each CpG was calculated in Illumina's GenomeStudio methylation module as  $\beta = \text{intensity of the methylated allele } (M) / (\text{intensity of the unmethylated allele } (U) + \text{intensity of the methylated allele } (M) + 100)$  (27). The  $\beta$  values were logit transformed to obtain the log ratio [ $\log \text{ ratio} = \log(\beta / 1 - \beta)$ ], which may have better statistical properties than the  $\beta$  values (29). Bisulfite conversion and DNA methylation were performed at Illumina, Inc. (San Diego, California) within a single month according to methods previously described (27). Quality control has been previously described (11). Briefly, duplicate samples and control samples were included on each plate in a blinded fashion, and a series of methylation controls (10%, 35%, 60%, and 85% methylated) was included on the first and last plates. The distribution of birth weight by analytical plate was similar, with overlapping means and interquartile ranges (data not shown). After adjustment for the covariates' associations, birth weight was not found to be different across DNA plates (Kruskal-Wallis  $P = 0.30$ ). Detection  $P$  values and multidimensional scaling were used to identify erroneous samples, and CpGs were excluded on the basis of missing data and genomic position. After quality control procedures, 1,068 subjects and 485,492 CpGs, including X and Y probes, were available for analysis.

### Statistical analysis of birth weight

We excluded 14 in vitro fertilization subjects and 9 subjects with missing covariates, leaving 1,046 subjects for analysis. We conducted an epigenome-wide analysis in which we evaluated the association between birth weight and methylation in cord blood at each of the 485,492 CpG sites, 1 at a time. Specifically, using birth weight as the dependent variable and the log ratio of methylation as the predictor, we applied robust linear regression with sandwich-based estimators of the covariance to accommodate potential outliers and heteroscedasticity (30). We adjusted for child sex, maternal plasma cotinine (11), parity, maternal age, dietary folate

not including supplements (24), asthma, gestational age at delivery, gestational age at delivery squared, preeclampsia, season of birth, and leukocyte cell-type proportions (31, 32) as potential confounders. Analyses using plasma instead of dietary folate yielded similar results. Given the number of statistical tests conducted, we report only CpGs that are significant after Bonferroni correction (485,492 statistical tests,  $P < 1.03 \times 10^{-7}$ ).

## RESULTS

The majority of the mothers were between the ages of 25 and 34 years. Approximately 40% were nulliparous. The distribution of maternal plasma cotinine levels suggested that approximately 13% were active smokers (plasma cotinine  $>56.8$  nmol/L (33)) at the time of blood collection, which occurred at approximately 18 weeks' gestation. The vast majority of births occurred at term and were of a healthy birth weight ( $\geq 2,500$  g). In total, 54% of the infants were boys. As described above (26), this cohort was designed to over-represent asthma at 3 years, which accounted for approximately 33% of this study population (Table 1).

For the multivariable analysis of differential DNA methylation in relation to birth weight, we identified 19 CpGs that reached Bonferroni significance ( $P < 1.03 \times 10^{-7}$ ) (Table 2, Web Figure 1 available at <http://aje.oxfordjournals.org/>). Of these, 13 were within genes and 6 were within intergenic regions. CpGs associated with birth weight were AT-rich interaction domain 5B (*MRF1*-like) (*ARID5B*) (2 CpGs); Kruppel-like factor 9 (*KLF9*); x-ray repair complementing defective repair in Chinese hamster cells 3 (*XRCC3*) (4 CpGs); phosphatidylinositol-binding protein 4 (*PEBP4*); sema domain, immunoglobulin domain, transmembrane domain, and short cytoplasmic domain, (semaphorin) 4C (*SEMA4C*); spondin 2, extracellular matrix protein (*SPON2*); ubiquitin-like with PHD and ring finger domains 1 (*UHRF1*); ankyrin repeat domain 11 (*ANKRD11*); and major facilitator superfamily domain containing 10 (*MFSD10*). The distributions of methylation values were transformed to approximate a normal distribution. Thus, the interpretation of the magnitude of the difference in birth weight in relation to methylation increases is as follows. For *ARID5B*, for each 1-logit increase in methylation of cg25953130 or cg02863179, birth weight was lower by 371 g or 341 g, respectively (Table 2, Figure 1). For *XRCC3*, for each 1-logit increase in methylation at cg02194129, birth weight was higher by approximately 727 g (Table 2, Figure 2). These models were adjusted for multiple confounders, including the estimated leukocyte cell-type proportions of each sample (31, 32). For the remaining probes found to be significant in Table 2, illustrations of the relationship between the untransformed methylation  $\beta$  value in relation to the birth weight residual after adjustment for important confounders can be found in Web Figure 2.

We conducted a sensitivity analysis in which we adjusted for caffeinated beverage intake in early pregnancy, maternal prepregnancy body mass index (weight (kg)/height (m)<sup>2</sup>), and maternal weight gain up until her completion of the third-trimester questionnaire. Inclusion of these covariates resulted in the loss of 128 participants. Adjustment for these additional covariates had little impact on the overall results when

**Table 1.** Characteristics of 1,046 Subjects in the Norwegian Mother and Child Cohort Study, 1999–2008

Characteristic	No.	%
Maternal age, years		
15–24	130	12.4
25–29	406	38.8
30–34	384	36.7
$\geq 35$	126	12.0
Parity		
0	425	40.6
1	432	41.3
$\geq 2$	189	18.1
Prenatal plasma cotinine, nmol/L		
Undetectable	725	69.3
$>0$ –56.8	188	18.0
56.9–388	68	6.5
$\geq 389$	65	6.2
Gestational age at delivery, weeks		
$<32$ ( $<224$ days)	1	0.1
32–36 (224–258 days)	36	3.4
37–41 (259–293 days)	926	88.5
$\geq 42$ ( $\geq 294$ days)	83	7.9
Infant birth weight, g		
$<2,500$	20	1.9
2,500–3,999	770	73.6
$\geq 4,000$	256	24.5
Infant sex		
Male	562	53.7
Female	484	46.3
Asthma at age 3 years	349	33.4

compared with a model of the same sample size with those covariates excluded (Web Figure 3A), although the following probes were no longer significant with this reduced sample size, which was likely primarily due to a loss of power: cg20076442, cg25124943, cg00605777, cg23127323, cg25162533, cg23369670, cg23237276, cg05993265, and cg24693803. Of the probes that remained significant, the magnitude of the regression coefficient in all cases preserved direction (increase or decrease in birth weight), with only small changes in magnitude (mean change = 6.5%). In addition, when we adjusted for measured plasma folate instead of dietary folate, there was no substantial change in the estimated  $P$  values (Web Figure 3B).

It is not yet clear how appropriate the available methods for correcting for leukocyte cell-type proportions (31) are in the setting of cord blood methylation, given that reference data sets are available for only adult peripheral blood (32). Therefore, we conducted analyses with and without this adjustment factor (Table 2). In these models, 22 CpG probes were significant at a Bonferroni-corrected threshold (Web Table 1). However, the CpGs did not overlap perfectly with those that were

**Table 2.** Associations of Selected CpGs<sup>a</sup> and Infant Birth Weight in the Norwegian Mother and Child Cohort Study, 1999–2008

CpG by Birth Weight Difference	Gene	Adjusted Mean Difference in Birth Weight (SE) <sup>b</sup>	Bonferroni-Corrected P Value <sup>c</sup>	Adjusted Mean Difference in Birth Weight (SE) <sup>d</sup>	Bonferroni-Corrected P Value <sup>c</sup>
Decrease in birth weight					
cg25953130	<i>ARID5B</i>	−371.26 (58.11)	$8.11 \times 10^{-5}$	−376.86 (53.93)	$1.35 \times 10^{-6}$
cg08005122		−493.38 (83.70)	$1.82 \times 10^{-3}$	−345.57 (74.14)	1.00
cg20076442		−302.79 (51.62)	$2.17 \times 10^{-3}$	−304.93 (47.00)	$4.22 \times 10^{-5}$
cg02863179	<i>ARID5B</i>	−340.99 (59.30)	$4.33 \times 10^{-3}$	−340.46 (51.76)	$2.32 \times 10^{-5}$
cg25124943		−480.24 (89.53)	$3.96 \times 10^{-2}$	−402.67 (77.99)	0.12
cg00049440	<i>KLF9</i>	−314.29 (58.69)	$4.14 \times 10^{-2}$	−302.06 (61.59)	0.45
Increase in birth weight					
cg02194129	<i>XRCC3</i>	726.57 (96.34)	$2.24 \times 10^{-8}$	403.00 (81.84)	0.41
cg17836177	<i>PEBP4</i>	558.39 (93.08)	$9.61 \times 10^{-4}$	481.80 (78.73)	$4.56 \times 10^{-4}$
cg12798040	<i>XRCC3</i>	326.29 (54.73)	$1.21 \times 10^{-3}$	268.26 (53.75)	0.29
cg00605777	<i>SEMA4C</i>	728.27 (122.89)	$1.50 \times 10^{-3}$	234.27 (83.10)	1.00
cg14172849	<i>XRCC3</i>	660.38 (112.59)	$2.17 \times 10^{-3}$	271.75 (76.66)	1.00
cg23127323	<i>SPON2</i>	323.05 (56.72)	$5.97 \times 10^{-3}$	257.23 (43.93)	$2.31 \times 10^{-3}$
cg25162533		382.67 (68.28)	$1.01 \times 10^{-2}$	371.26 (65.87)	$8.40 \times 10^{-3}$
cg23369670	<i>XRCC3</i>	557.29 (99.73)	$1.12 \times 10^{-2}$	144.55 (66.65)	1.00
cg17714703	<i>UHRF1</i>	296.96 (54.11)	$1.97 \times 10^{-2}$	322.68 (47.99)	$8.64 \times 10^{-6}$
cg08420923	<i>ANKRD11</i>	493.22 (91.53)	$3.45 \times 10^{-2}$	457.16 (75.05)	$5.44 \times 10^{-4}$
cg23237276		523.19 (97.67)	$4.12 \times 10^{-2}$	382.82 (73.05)	0.08
cg05993265	<i>MFSD10</i>	442.00 (82.59)	$4.23 \times 10^{-2}$	236.24 (67.26)	1.00
cg24693803		538.69 (101.12)	$4.84 \times 10^{-2}$	457.97 (88.27)	0.10

Abbreviations: *ANKRD11*, ankyrin repeat domain 11; *ARID5B*, AT-rich interaction domain 5B (*MRF1*-like); CpG, cytosine-guanine dinucleotide; *KLF9*, Kruppel-like factor 9; *MFSD10*, major facilitator superfamily domain containing 10; *PEBP4*, phosphatidylethanolamine-binding protein 4; SE, standard error; *SEMA4C*, sema domain, immunoglobulin domain, transmembrane domain, and short cytoplasmic domain, (semaphorin) 4C; *SPON2*, spondin 2, extracellular protein; *UHRF1*, ubiquitin-like with PHD and ring finger domains 1; *XRCC3*, x-ray repair complementing defective repair in Chinese hamster cells 3.

<sup>a</sup> From Infinium HumanMethylation450 BeadChip (Illumina, Inc., San Diego, California).

<sup>b</sup> Per logit increase in methylation fraction, including covariates for child sex, maternal plasma cotinine, parity, maternal age, dietary folate not including supplements, asthma, gestational age at delivery, gestational age at delivery squared, preeclampsia, season of birth, and leukocyte cell-type proportions.

<sup>c</sup> Unadjusted *P* values multiplied by 485,492 (number of tests). The threshold for significance remains  $P < 0.05$  ( $5 \times 10^{-2}$ ).

<sup>d</sup> Per logit increase in methylation fraction, including covariates for factors listed above with leukocyte cell-type proportion removed.

significant after adjustment for cell type. Among the 19 probes that were significant in models adjusted for cell-type proportions, 8 CpGs remained significant without adjustment for cell type (Table 2). Interestingly, associations with all of the *XRCC3* CpGs were significant only in the models with cell-type adjustment.


## DISCUSSION

In this analysis of a homogeneous Norwegian population, we report significant associations between CpGs in cord blood DNA and birth weight. We identified associations in 9 genes, 2 of which (*ARID5B* (2 CpGs) and *XRCC3* (4 CpGs)) had multiple significant CpGs. This is one of the first studies to examine DNA methylation across the genome in relation to birth weight and the first to have used the 450K platform.

Additionally, our use of a large, well-defined birth cohort provides essential covariate data to adjust for confounders of the methylation–birth weight relationships.

We found an inverse association between *ARID5B* methylation and birth weight (higher methylation fraction associated with lower birth weight) (Figure 1). *ARID5B* (also known as *MRF2/MRF-2*), is a transcriptional coactivator that plays a key role in adipogenesis. *ARID5B* knockout mice have a high rate of neonatal death and reduced lipid accumulation, which manifests in significantly lower weight from postnatal day 5 onward (34). Both full and partial *ARID5B* knockouts are resistant to weight gain and obesity, even after high-fat dietary challenges (34). One possible mechanism explaining these findings is the modulation of leptin levels, given that down-regulation of *ARID5B* results in increased expression of leptin, an important regulator of energy balance, insulin resistance, and metabolism (35).






**Figure 1.** Cytosine-guanine dinucleotide methylation  $\beta$  values for significant AT-rich interactive domain 5B (*MRF1*-like) (*ARID5B*) probes in relation to birth weight residual in the Norwegian Mother and Child Cohort Study, 1999–2008. Untransformed methylation  $\beta$  values for *ARID5B* A) cg25953130 ( $P = 8.11 \times 10^{-5}$ ) and B) cg02863179 ( $P = 4.33 \times 10^{-3}$ ) are plotted against the birth weight residual after adjustment for child sex, maternal plasma cotinine, parity, maternal age, dietary folate not including supplements, asthma, gestational age at delivery, gestational age at delivery squared, preeclampsia, season of birth, and leukocyte cell-type proportions. Methylation  $\beta$  values were divided into 8 equally spaced intervals. Both show a roughly linearly declining trend in birth weight with increasing methylation fraction.

The *ARID5B* CpGs associated with birth weight in our study are located in the gene body, which typically results in enhanced expression (4–6). However, using gene expression and methylation data from 41 normal breast tissue samples in The Cancer Genome Atlas (<http://cancergenome.nih.gov>), we observed an inverse relationship between methylation at the 2 significant CpGs in the *ARID5B* gene and *ARID5B* expression. Although the effect size was large, the correlation was not statistically significant ( $P = 0.15$ ). Thus, further systematic functional studies are required to describe the relationship between methylation at this site and *ARID5B* gene expression in cord blood samples. Of potential interest, polymorphisms in the *ARID5B* gene have been associated with increased risk for acute lymphoblastic leukemia (36, 37), coronary artery disease (38), and type 2 diabetes (39).

*XRCC3* is a critical DNA repair gene, whose function during development is ensuring the accurate duplication of cells through homologous recombination (40, 41). In *XRCC3*-deficient hamster cell lines, repair of DNA double-strand breaks is decreased 25-fold (41). Infante-Rivard et al. (42) examined a coding polymorphism (Thr241Met) in *XRCC3* in relation to small for gestational age and found no overall increased risk of small for gestational age related to genotype, although women who smoked in the third trimester and carried the variant that encodes threonine were at somewhat increased

risk of having offspring that were small for gestational age. However, there are no other studies that have reported an association of *XRCC3* with any fetal growth parameter. In our study, 4 *XRCC3* CpGs were associated with increased birth weight, suggesting an inverse correlation between *XRCC3* expression (via increased methylation) and birth weight. However, these associations were significant only in models adjusted for peripheral blood leukocyte cell-type proportion and, thus, require more research to fully understand.

Other genes highlighted in our study have been shown to be important in developmental processes, although their relation to fetal growth in particular has not been addressed. *UHRF1* has multiple domains that bind chromatin and has been shown to be important in the maintenance of DNA methylation (43). In mice, *UHRF1* is highly expressed in pluripotent stem cells, as opposed to differentiated tissue (44), and genetic ablation of *UHRF1* has been shown to result in genomic hypomethylation (45, 46). Yippee-like 3 (*Drosophila*) (*YPEL3*) is regulated by p53 and induces cellular senescence. It has growth-inhibitory effects in both normal and tumor cell lines (47). In our data, increased methylation (presumably negatively regulating gene expression) was associated with increased birth weight, which would represent a logically consistent direction of association. *ANKRD11* enhances the transcriptional activity of p53 (48) and is of increasing



**Figure 2.** Cytosine-guanine dinucleotide methylation  $\beta$  values for significant x-ray repair complementing defective repair in Chinese hamster cells 3 (*XRC3*) probes in relation to birth weight residual. Untransformed methylation  $\beta$  values of *XRC3* A) cg02194129 ( $P=2.24 \times 10^{-8}$ ), B) cg12798040 ( $P=1.21 \times 10^{-3}$ ), and C) cg14172849 ( $P=2.17 \times 10^{-3}$ ) are plotted against the birth weight residual after adjustment for child sex, maternal plasma cotinine, parity, maternal age, dietary folate not including supplements, asthma, gestational age at delivery, gestational age at delivery squared, preeclampsia, season of birth, and leukocyte cell-type proportions. Methylation  $\beta$  values were divided into 8 equally spaced intervals. All show a roughly linearly increasing trend in birth weight with increasing methylation fraction.

interest in relation to autism (49). Mutations in *ANKRD11* are associated with KBG syndrome, a rare genetic disease characterized by short stature, typical facial dysmorphism, dental

issues, and developmental delay (50). In KBG syndrome, birth weight is typically normal but birth length is often below the third percentile.

Genes are turned on and off dynamically during development (51); thus, methylation, as a means of controlling gene expression and the activation of biological cascades, is important for fetal development and parturition. However, in the current and previous studies (17, 18, 52, 53), methylation status is measured only once (at delivery), and therefore may not always generalize to antecedent periods or to births that occur remote from term. Indeed, all studies of cord blood methylation and birth outcomes are, by their nature, cross-sectional (i.e., exposure (methylation) and outcome (birth weight) are measured simultaneously). The methylation status of cord blood CpGs may be the consequence of exposures experienced during pregnancy that result in changes in the timing of delivery or growth of the fetus, or alternatively, it may reflect the developmental process ongoing at the time of delivery. Because of the temporal uncertainty and influence of other factors on cord blood methylation patterns, we have presented our results as associations without making strong causal arguments.

The strengths of our study are many. First, we used the Illumina 450K technology, which provides state-of-the-art epigenome-wide coverage. Second, our study was nested within MoBa, a population-based cohort of Norwegian women recruited early in pregnancy. The MoBa cohort is racially homogeneous, which is beneficial in the setting of birth weight analyses given the strong and consistent racial disparities in mean birth weight across the spectrum of gestational age (47). Norwegians also have nationalized health care, ensuring the adequacy of free antenatal care across the socioeconomic spectrum. These beneficial characteristics of MoBa would tend to reduce the likelihood of residual confounding by any unmeasured factors associated with race and access to care.

A significant strength of our study is that we were able to adjust for strong known correlates of birth weight (such as prenatal smoking, as measured by plasma cotinine levels in the second trimester), parity, maternal age, and other factors associated with the probability of selection into this nested study. Although the original study was sampled to over-represent asthma cases at 3 years, our results adjusted for this selection factor and were found to be robust on the basis of analyses of only the random subcohort (data not shown). Moreover, ours is the largest study to date to examine cord blood methylation in relation to birth weight. We observed somewhat different associations when we adjusted for estimated leukocyte cell-type proportions, which have been shown to exhibit important variation in methylation profiles (31, 32). However, it is not yet clear how appropriate these methods are in the setting of cord blood. For example, cord blood contains more nucleated red blood cells than does adult blood, and these might vary by gestational age, although the percentage of nucleated red blood cells of all nucleated cells remains low in cord blood (3.2%) (54). Further research examining variability in cord blood cell population methylation profiles is required.

In conclusion, using cord blood DNA, we identified a small number of CpGs in 9 genes, including multiple significant CpGs in *ARID5B* and *XRCC3*, which are associated with birth weight in a large population-based cohort. Some biological plausibility for a role for *ARID5B* in particular in fetal growth is provided by associations with postnatal growth and lipid

accumulation in mice. The other genes have been less well studied, but many are involved in developmental processes. Although the underlying mechanism and associated causal processes are unclear, these findings may provide novel insights into the role of epigenetic modifications, including methylation, in the regulation of fetal growth and parturition.

## ACKNOWLEDGMENTS

Author affiliations: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Stephanie M. Engel, Andrew F. Olshan); Epidemiology Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina (Bonnie R. Joubert, Stephanie J. London); Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (Michael C. Wu); Institute Management and Staff, Norwegian Institute of Public Health, Oslo, Norway (Siri E. Håberg); Department of Clinical Science, University of Bergen, Bergen, Norway (Per Magne Ueland); Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway (Per Magne Ueland); Norwegian Institute of Public Health, Division of Epidemiology, Oslo, Norway (Wenche Nystad, Stein Emil Vollset); Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway (Roy M. Nilsen, Stein Emil Vollset); and Biostatistics Branch, Division of Intramural Research, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina (Shyamal D. Peddada)

This research was supported in part by the intramural research program of the National Institute of Environmental Health Sciences (grant Z01-ES-49019) and the National Institute of Environmental Health Sciences (grant P30ES010126). The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health and the Ministry of Education and Research and the National Institute of Environmental Health Sciences (contract NO-ES-75558), the National Institute of Neurological Disorders and Stroke (grant 1 UO1 NS 047537-01), and the Norwegian Research Council/Functional Genomics (grant 151918/S10). Support for Drs. Engel and Wu was provided by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (grant R01HD058008).

S.M.E., B.R.J., and M.C.W. contributed equally to the paper and should each be considered first author.

Conflict of interest: none declared.

## REFERENCES

1. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. *Science*. 1999;286(5439):481–486.
2. Bernal AJ, Jirtle RL. Epigenomic disruption: the effects of early developmental exposures. *Birth Defects Res A Clin Mol Teratol*. 2010;88(10):938–944.

3. Heijmans BT, Tobi EW, Lumey LH, et al. The epigenome: archive of the prenatal environment. *Epigenetics*. 2009;4(8):526–531.
4. Ball MP, Li JB, Gao Y, et al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. *Nat Biotechnol*. 2009;27(4):361–368.
5. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet*. 2012;13(7):484–492.
6. Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. *Nature*. 2010;466(7303):253–257.
7. Eggermann T. Silver-Russell and Beckwith-Wiedemann syndromes: opposite (epi)mutations in 11p15 result in opposite clinical pictures. *Horm Res*. 2009;71(suppl 2):30–35.
8. Lee JT, Bartolomei MS. X-inactivation, imprinting, and long noncoding RNAs in health and disease. *Cell*. 2013;152(6):1308–1323.
9. Bjornsson HT, Sigurdsson MI, Fallin MD, et al. Intra-individual change over time in DNA methylation with familial clustering. *JAMA*. 2008;299(24):2877–2883.
10. Hoyo C, Murtha AP, Schildkraut JM, et al. Methylation variation at *IGF2* differentially methylated regions and maternal folic acid use before and during pregnancy. *Epigenetics*. 2011;6(7):928–936.
11. Joubert BR, Håberg SE, Nilsen RM, et al. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. *Environ Health Perspect*. 2012;120(10):1425–1431.
12. Murphy SK, Adigun A, Huang Z, et al. Gender-specific methylation differences in relation to prenatal exposure to cigarette smoke. *Gene*. 2012;494(1):36–43.
13. Liu Y, Murphy SK, Murtha AP, et al. Depression in pregnancy, infant birth weight and DNA methylation of imprint regulatory elements. *Epigenetics*. 2012;7(7):735–746.
14. Hoyo C, Fortner K, Murtha AP, et al. Association of cord blood methylation fractions at imprinted insulin-like growth factor 2 (*IGF2*), plasma *IGF2*, and birth weight. *Cancer Causes Control*. 2012;23(4):635–645.
15. St-Pierre J, Hivert MF, Perron P, et al. *IGF2* DNA methylation is a modulator of newborn's fetal growth and development. *Epigenetics*. 2012;7(10):1125–1132.
16. Tobi EW, Heijmans BT, Kremer D, et al. DNA methylation of *IGF2*, *GNASAS*, *INSIGF* and *LEP* and being born small for gestational age. *Epigenetics*. 2011;6(2):171–176.
17. Gordon L, Joo JE, Powell JE, et al. Neonatal DNA methylation profile in human twins is specified by a complex interplay between intrauterine environmental and genetic factors, subject to tissue-specific influence. *Genome Res*. 2012;22(8):1395–1406.
18. Turan N, Ghalwash MF, Katari S, et al. DNA methylation differences at growth related genes correlate with birth weight: A molecular signature linked to developmental origins of adult disease? *BMC Med Genomics*. 2012;5:10.
19. Magnus P, Irgens LM, Haug K, et al. Cohort profile: the Norwegian Mother and Child Cohort Study (MoBa). *Int J Epidemiol*. 2006;35(5):1146–1150.
20. Nilsen RM, Vollset SE, Gjessing HK, et al. Self-selection and bias in a large prospective pregnancy cohort in Norway. *Paediatr Perinat Epidemiol*. 2009;23(6):597–608.
21. Brantsaeter AL, Haugen M, Alexander J, et al. Validity of a new food frequency questionnaire for pregnant women in the Norwegian Mother and Child Cohort Study (MoBa). *Matern Child Nutr*. 2008;4(1):28–43.
22. Haugen M, Brantsaeter AL, Alexander J, et al. Dietary supplements contribute substantially to the total nutrient intake in pregnant Norwegian women. *Ann Nutr Metab*. 2008;52(4):272–280.
23. Norwegian Food Safety Authority. *Norwegian Food Composition Database 2013*. Oslo, Norway: Norwegian Directorate of Health and University of Oslo; 2013.
24. Nilsen RM, Vollset SE, Monsen AL, et al. Infant birth size is not associated with maternal intake and status of folate during the second trimester in Norwegian pregnant women. *J Nutr*. 2010;140(3):572–579.
25. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. *Acta Obstet Gynecol Scand*. 2000;79(6):435–439.
26. Håberg SE, London SJ, Nafstad P, et al. Maternal folate levels in pregnancy and asthma in children at age 3 years. *J Allergy Clin Immunol*. 2011;127(1):262–264.
27. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. *Genomics*. 2011;98(4):288–295.
28. Sandoval J, Heyn H, Moran S, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. *Epigenetics*. 2011;6(6):692–702.
29. Du P, Zhang XA, Huang CC, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. *BMC Bioinformatics*. 2010;11:587.
30. Huber PJ. Robust regression: asymptotics, conjectures and Monte Carlo. *Ann Stat*. 1973;1(5):799–821.
31. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics*. 2012;13:86.
32. Reinius LE, Acevedo N, Joerink M, et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. *PLoS One*. 2012;7(7):e41361.
33. Shaw GM, Carmichael SL, Vollset SE, et al. Mid-pregnancy cotinine and risks of orofacial clefts and neural tube defects. *J Pediatr*. 2009;154(1):17–19.
34. Whitson RH, Tsark W, Huang TH, et al. Neonatal mortality and leanness in mice lacking the ARID transcription factor Mrf-2. *Biochem Biophys Res Commun*. 2003;312(4):997–1004.
35. Dong J, Ishimori N, Paigen B, et al. Role of modulator recognition factor 2 in adipogenesis and leptin expression in 3T3-L1 cells. *Biochem Biophys Res Commun*. 2008;366(2):551–555.
36. Healy J, Richer C, Bourgey M, et al. Replication analysis confirms the association of *ARID5B* with childhood B-cell acute lymphoblastic leukemia. *Haematologica*. 2010;95(9):1608–1611.
37. Treviño LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet*. 2009;41(9):1001–1005.
38. Wang G, Watanabe M, Imai Y, et al. Genetic variations of Mrf-2/ARID5B confer risk of coronary atherosclerosis in the Japanese population. *Int Heart J*. 2008;49(3):313–327.
39. Wang G, Watanabe M, Imai Y, et al. Associations of variations in the *MRF2/ARID5B* gene with susceptibility to type 2 diabetes in the Japanese population. *J Hum Genet*. 2012;57(11):727–733.
40. Griffin CS, Simpson PJ, Wilson CR, et al. Mammalian recombination-repair genes *XRCC2* and *XRCC3* promote correct chromosome segregation. *Nat Cell Biol*. 2000;2(10):757–761.
41. Pierce AJ, Johnson RD, Thompson LH, et al. *XRCC3* promotes homology-directed repair of DNA damage in mammalian cells. *Genes Dev*. 1999;13(20):2633–2638.



42. Infante-Rivard C, Weinberg CR, Guiguet M. Xenobiotic-metabolizing genes and small-for-gestational-age births: interaction with maternal smoking. *Epidemiology*. 2006; 17(1):38–46.
43. Rothbart SB, Krajewski K, Nady N, et al. Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. *Nat Struct Mol Biol*. 2012;19(11): 1155–1160.
44. Pichler G, Wolf P, Schmidt CS, et al. Cooperative DNA and histone binding by Uhrf2 links the two major repressive epigenetic pathways. *J Cell Biochem*. 2011;112(9):2585–2593.
45. Bostick M, Kim JK, Esteve PO, et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. *Science*. 2007;317(5845):1760–1764.
46. Sharif J, Muto M, Takebayashi S, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. *Nature*. 2007;450(7171):908–912.
47. Hauck FR, Tanabe KO, Moon RY. Racial and ethnic disparities in infant mortality. *Semin Perinatol*. 2011;35(4): 209–220.
48. Neilsen PM, Cheney KM, Li CW, et al. Identification of ANKRD11 as a p53 coactivator. *J Cell Sci*. 2008;121(Pt 21): 3541–3552.
49. Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet*. 2008;82(2):477–488.
50. Sirmaci A, Spiliopoulos M, Brancati F, et al. Mutations in *ANKRD11* cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. *Am J Hum Genet*. 2011;89(2):289–294.
51. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. *Nature*. 2007;447(7143):425–432.
52. Lee H, Jaffe AE, Feinberg JI, et al. DNA methylation shows genome-wide association of *NFIX*, *RAPGEF2* and *MSRB3* with gestational age at birth. *Int J Epidemiol*. 2012;41(1):188–199.
53. Schroeder JW, Conneely KN, Cubells JC, et al. Neonatal DNA methylation patterns associate with gestational age. *Epigenetics*. 2011;6(12):1498–1504.
54. Proytcheva MA. Issues in neonatal cellular analysis. *Am J Clin Pathol*. 2009;131(4):560–573.